Immunovant Inc. (IMVT)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
Immunovant (IMVT) reported earnings 30 days ago. What's next for the stock?
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential
Immunovant's underlying bull case has now moved away from batoclimab and toward IMVT-1402. This newer asset has encouraging data for difficult-to-treat RA. By week 16, 72.7% of hard-to-treat RA patients had good responses with IMVT-1402. IMVT also has a solid balance sheet this time around. And management believes its runway is sufficient through their next readouts.
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
Roivant (ROIV) remains a Buy as its unique 'vant' structure rapidly advances and monetizes blockbuster assets, notably through Immunovant's IMVT-1402 in rheumatoid arthritis. IMVT-1402 delivered strong Phase 2 efficacy in difficult-to-treat rheumatoid arthritis, with ACR20/50/70 rates of 72.7%, 54.5%, and 35.8%, respectively. ROIV's financial position is robust, ending the quarter with $4.3 billion in cash and a management-asserted runway to profitability.
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data
Immunovant stock jumps 35% as strong early IMVT-1402 data in rheumatoid arthritis boosts confidence despite a wider Q4 loss.
IMVT Stock Falls 2.4% as Batoclimab Misses Late-Stage Study Endpoints
Immunovant slips 2.4% after batoclimab misses key phase III endpoints in thyroid eye disease trials, despite stable safety and signs of biological activity.
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript
Immunovant's treatment for eye disease fails late-stage trial
Immunovant said on Thursday that its therapy to treat a type of eye disease failed to meet the main goals in a late-stage study.
A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?
Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 million based on quarterly average pricing. By quarter's end, the position had grown to roughly $35 million, reflecting both the new shares and price gains during the period.
Immunovant Stock Surges 17% in 3 Months: What's Driving It?
IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.
IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus
Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript
Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript
